Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia

This study is a randomized, double-blind, multicenter, placebo parallel-controlled Phase II clinical study designed to evaluate the clinical efficacy and safety of TJ0113 Capsule in patients with sarcopenia. The entire study plans to enroll 204 participants with sarcopenia. Eligible participants will be stratified by age (\< 70 years or ≥ 70 years to ≤ 80 years or \> 80 years) and block-randomized in a 1:1:1:1 ratio into 4 groups (TJ0113 Capsule 100 mg dose group; TJ0113 Capsule 200 mg dose group; TJ0113 Capsule 400 mg dose group; placebo group), with 51 participants per group. Participants in the placebo group will then be re-randomized in a 1:1:1 ratio to the respective dose groups (100 mg, 200 mg, and 400 mg). After randomization, study participants will receive continuous oral administration for 26 weeks with efficacy and safety evaluations, followed by a 1-week follow-up period after the end of treatment.

NCT Number	NCT07620938
Lead Sponsor	Hangzhou PhecdaMed Co., Ltd.
Conditions	Sarcopenia
Enrollment	204 participants
Start Date	2026-06-12
Primary Completion	2027-08-22 (estimated)
Study Completion	2027-10-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-05